Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Windler

Showing results (31-40 of 102) with videos related to

Pageof 11
Sort By:
Der Internist|February 22, 2015
[HDL and atherosclerotic cardiovascular diseases]E Windler, S Nitschmann
Der Internist|July 15, 2015
[Effects of glycemic index on cardiovascular risk factors: The OmniCarb randomized clinical trial]E Windler, S Nitschmann
Der Internist|July 1, 1985
[Physiology and pathophysiology of lipoprotein metabolism--relation to hyperlipemias and arteriosclerosis]H Greten, E Windler
Der Internist|December 5, 2015
[New therapy option for type 2 diabetes mellitus: EMPA-REG study]E Windler, S Nitschmann
Der Internist|December 1, 1996
[Lipid therapy. Goal and use in prevention of coronary heart disease]E Windler, H Greten
Atherosclerosis. Supplements|May 5, 2015
Cholesterol-lowering therapy: Old evidence, new guidelines--Which one to follow? A critical appraisalE Windler, B-Chr Zyriax
Herz|February 1, 2002
[Life style changes for prevention of coronary heart disease]E Windler, B C Zyriax
Journal of Lipid Research|May 1, 1985
Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liverE Windler, R J Havel
Herz|June 1, 1997
[Goals and practical implementation of lipid therapy in coronary heart disease]F U Beil, E Windler
Herz|June 1, 1997
[Rationale for lipid therapy. Prevention or treatment of coronary heart disease?]E Windler, F U Beil
Pageof 11

Showing results (31-40 of 102) with videos related to

Sort By:
Pageof 11
Der Internist|February 22, 2015
[HDL and atherosclerotic cardiovascular diseases]E Windler, S Nitschmann
Der Internist|July 15, 2015
[Effects of glycemic index on cardiovascular risk factors: The OmniCarb randomized clinical trial]E Windler, S Nitschmann
Der Internist|July 1, 1985
[Physiology and pathophysiology of lipoprotein metabolism--relation to hyperlipemias and arteriosclerosis]H Greten, E Windler
Der Internist|December 5, 2015
[New therapy option for type 2 diabetes mellitus: EMPA-REG study]E Windler, S Nitschmann
Der Internist|December 1, 1996
[Lipid therapy. Goal and use in prevention of coronary heart disease]E Windler, H Greten
Atherosclerosis. Supplements|May 5, 2015
Cholesterol-lowering therapy: Old evidence, new guidelines--Which one to follow? A critical appraisalE Windler, B-Chr Zyriax
Herz|February 1, 2002
[Life style changes for prevention of coronary heart disease]E Windler, B C Zyriax
Journal of Lipid Research|May 1, 1985
Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liverE Windler, R J Havel
Herz|June 1, 1997
[Goals and practical implementation of lipid therapy in coronary heart disease]F U Beil, E Windler
Herz|June 1, 1997
[Rationale for lipid therapy. Prevention or treatment of coronary heart disease?]E Windler, F U Beil
Pageof 11